uniQure price target raised to $20 from $14 at RBC Capital

RBC Capital raised the firm’s price target on uniQure (QURE) to $20 from $14 and keeps an Outperform rating on the shares. uniQure announced that following its Type B meeting with the FDA, the Agency has agreed that data from its ongoing Phase I/II study may be sufficient for accelerated approval. Overall, RBC thinks the update materially de-risks the approach, shrinks timelines, and is likely to facilitate strategic discussions. The firm is a buyer into strength.